Precision BioSciences Advances PBGENE-HBV Trials for Chronic Hepatitis B Treatment

Precision BioSciences Moves Forward with PBGENE-HBV Clinical Trials

Precision BioSciences, Inc. makes significant strides in the fight against chronic hepatitis B with the recent clearance of its first clinical trial application (CTA) for its lead program, PBGENE-HBV. This milestone is crucial, as chronic hepatitis B affects around 300 million people worldwide, creating an urgent need for effective treatments. PBGENE-HBV employs an innovative dual modality approach designed to eliminate covalently closed circular DNA (cccDNA) and deactivate integrated HBV genomes, targeting the underlying causes of viral persistence. This unique strategy positions Precision BioSciences as a key player in advancing gene editing therapies within the biopharmaceutical landscape.

The company’s CEO, Michael Amoroso, emphasizes the urgency of patient dosing and the importance of securing additional regulatory approvals to expedite enrollment in the Phase 1 trial. The approval received in Moldova for the clinical trial represents not only a breakthrough for Precision but also an opportunity to leverage the country’s expertise in hepatitis B studies. With the robust preclinical safety data suggesting PBGENE-HBV’s potential to target and eliminate hepatitis B cccDNA without compromising human genome integrity, the company is optimistic about its upcoming clinical endeavors. The favorable tolerability results from non-human primate studies further bolster the confidence in the therapy’s safety profile.

Looking ahead, Precision BioSciences plans to disclose more details about PBGENE-HBV’s clinical strategy on November 15, 2024, just before the AASLD conference. This timeline is aligned with the company’s commitment to sharing Phase 1 trial data throughout 2025. Additionally, Precision is preparing to submit an investigational new drug (IND) application for its second program, PBGENE-3243, which targets m.3243-associated mitochondrial disease. This dual focus on advancing both PBGENE-HBV and PBGENE-3243 underscores Precision's commitment to addressing critical unmet medical needs through innovative gene editing technologies.

In the backdrop of these advancements, Precision BioSciences continues to solidify its position in the biopharmaceutical sector. The encouraging developments surrounding PBGENE-HBV not only highlight the potential of gene-editing technologies but also reflect the company’s strategic efforts to address pressing global health challenges. As Precision gears up for the clinical phases of its lead program, the biopharmaceutical community eagerly anticipates the implications of these innovations in the treatment landscape for chronic hepatitis B and beyond.